A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure

Inclusion Criteria: * If female, must be at least 2 years post-menopausal or have bilateral oophorectomy, hysterectomy or documented sterility * If male, must have documented sterility (by verbal report or previous vasectomy), or if non-sterile, must agree to use barrier contraception for the entire duration of the trial and until 3 months after the last dose of investigational product. Must also agree not to donate sperm during the study and up to 3 months after the last dose of investigational product * Stable coronary disease without unstable angina or acute coronary syndrome in the last 6 months * All cardiac medications, specifically beta-blockers, renin-angiotensin system inhibitors, aldosterone antagonists, hydralazine and nitrates are at a stable dose (at least 4 weeks) prior to Day 1 Exclusion Criteria: * Any previous exposure to GGF2 or other neuregulins * Initiation or change of a prescription medication within the 2 weeks prior to Day 1, and/or concomitant medication regimen is expected to change during the course of the study * Known allergic reaction to midazolam, or any of the components of midazolam syrup (including cherry flavoring), or components of GGF2 diluent * Known specific hepatic disease; total bilirubin \>2 mg/dL, AST \> 100 IU * History of hepatic impairment (hepatitis B and C) * Type I Diabetes * Documented stroke or transient ischemic attack (TIA) within 2 months of study enrollment